LOS ANGELES, July 8, 2014 (GLOBE NEWSWIRE) -- RadNet Inc.(Nasdaq:RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 250 owned and/or operated outpatient imaging centers, announced it has joined a research study, the Imaging and Genetic Biomarkers for Alzheimer's Disease (ImaGene) study. The study is supported in part by GE Healthcare and sponsored by the Jim Easton Consortium for Alzheimer's Disease Drug Discovery and Biomarkers, and, the National Institute of Aging.